123ArticleOnline Logo
Welcome to 123ArticleOnline.com!

ALL >> Business >> View Article

Harver Group Targets Biotech Bull

By Author: Harver Group
Total Articles: 26

Jul. 24, 2013 - CHUO-KU, Japan -- Due to the huge increase in staff and board members buying stock in Synta Pharmaceuticals, and the successful trials of Synta Pharmaceuticals latest cancer drug Ganetespib, Pharmaceutical Analysts at Harver Group are now strongly recommending the stock as a buy to investors.

Stephen James, Director of Private Equity at Harver Group in Tokyo, commented “A huge indicator for me that a stock is about to take off is insider buying. We have seen quite a bit of this over the past few weeks at Synta Pharmaceuticals, Hedge Fund Manager, Bruce Kovner who has also been on the board of directors since 2002, has bought 3 million shares for just over $13 million. President and CEO Safi Bachall also bought 10,000 shares bring his total to almost 2 million.”

Synta Pharmaceuticals (SNTA) is a biopharmaceutical corporation which creates, develops, and commercializes drugs that extend and increase the standard of living of patients with cancer and other chronic diseases. The Company has a unique library of propriety chemical compounds acquired over two decades from academic and industrial sources. These compounds are optimized through a variety of techniques to create new drug candidates.

Their most exciting new drug candidate is called Ganetespib and is used to treat lung, breast, colorectal, and hemolytic cancer. Ganetespib is a small molecular inhibitor of heat shock protein 90 (Hsp90) which is required for the maturation and activation of a number of proteins. Cancer cells thrive in the presence of Hsp90, inhibiting it can greatly reduce tumors proliferation. The drug has been tested on over 700 patients in 20 clinical trials. Although trials are not finished and the company has not released a full report, the drug has shown a lot of promise.

Nathan Marx, Head of Investment Analysis said, “Although their share price has dropped from its $10 a share high in April, I expect it to return to this price in the next three months and I am recommending my clients to buy.” Peter Anderson, Senior Vice President of Mergers and Acquisitions at Harver Group said

“This is an exciting company, on the verge of a major breakthrough, displaying all the signs of a strong financial instrument for these coming quarters, so I’m confident our clients will see growth in this area”.

Total Views: 1255Word Count: 382See All articles From Author

Business Articles

1. Finding The Right Camera Bag Could Be Easy With The Discussed Tips
Author: Pricedesi

2. Contact The Right Audience And Executives With Pharmaceutical Companies Mailing List
Author: Jane Cannon

3. Understanding The Relevance Of Real Estate Services In 2018
Author: James Hopkins

4. Get Access To Highly Focused Quickbooks Users Email List
Author: Andrew Rayel

5. What Happiness Means To You- Certified Quantum Suc
Author: Christy Whitman

6. Some Very Basic Tricks To Get Your Accounting Right
Author: capecoralaccounting

7. Accounting Service For A Small Business Confirm A Smooth Running
Author: capecoralaccounting

8. Injured By A Drunk Driver Here’s What To Do
Author: 0

9. You Have To Visit The Bank's Site On The Web And Fill In The Application
Author: Brandon Jones

10. Bed Bug Treatment That's Effective And Affordable
Author: Steve Stein

11. Here Are 5 Tips That Will Keep
Author: 0

12. Here’s All That Your Angry Customers Want Your Business To Learn!
Author: Surabhi Joshi

13. Plastic Model Aircraft
Author: David1sport

14. An Ultimate Guide To Chlorinated Polyethylene And Its Properties
Author: Power2SME

15. Schramsberg Blanc De Blancs 2012
Author: 0

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: